Pfizer, Arvinas Post Upbeat Data From Breast Cancer Study

Pfizer PFE and partner Arvinas ARVN reported interim data from a phase Ib cohort of the ARV-471-mBC-101 study evaluating the investigational combination of vepdegestrant (formerly ARV-471) and CDK4/6 inhibitor Ibrance (palbociclib) in certain patients with heavily pre-treated breast cancer.